Sermorelin

Sermorelin acetate (GHRH1-29) is a synthetic fragment of endogenous growth hormone–releasing hormone (GHRH) designed to bind and activate GHRH receptors in the anterior pituitary. Although shorter than the full 44–amino-acid human GHRH peptide, GHRH1-29 retains full biological activity in stimulating pulsatile growth hormone (GH) secretion in experimental models.

Specifications

Synonyms: GHRH(1-29), Sermorelin Acetate, GRF 1-29
Molecular Formula: C₁₄₉H₂₅₂N₄₄O₄₂S
Molecular Weight: 3357.9 g/mol
Class: GHRH analog / Pituitary GH Secretagogue

Mechanism of Action: GHRH Receptor Activation & GH Pulsatility

Research demonstrates that Sermorelin binds the GHRH receptor (GHRHR) on pituitary somatotropes, triggering:

• cAMP accumulation via Gs protein coupling

• Activation of PKA and CREB

• Increased GH gene transcription

• Enhanced pulsatile GH release rather than continuous stimulation

Studies also show that GHRH1-29 preserves physiologic negative feedback from IGF-1, maintaining a regulated secretory pattern similar to endogenous GH signaling.

Experimental studies have reported that Sermorelin:

• Increases amplitude of GH pulses

• Enhances GH responsiveness to endogenous stimuli

• Supports pituitary somatotroph proliferation in some animal models

• Avoids receptor desensitization typical of non-GHRH secretagogues

Growth Hormone, IGF-1, and Metabolic Research

Preclinical and controlled human research on GHRH analogs, including Sermorelin, describe several physiological actions:

1. IGF-1 Modulation

Sermorelin-stimulated GH release increases hepatic IGF-1 production, which participates in:

• Protein synthesis

• Muscle recovery

• Tissue repair

• Anticatabolic signaling pathways

A randomized trial in adults demonstrated dose-dependent increases in serum GH and IGF-1 following Sermorelin infusion.

2. Sleep-Related GH Secretion

GH secretion peaks during slow-wave sleep. Rodent studies show that GHRH analogs enhance the intensity and duration of deep sleep phases, aligning Sermorelin activity with natural circadian physiology.

3. Neuroendocrine and Cognitive Research

Central GHRH signaling has been linked to:

• Memory consolidation

• Stress-axis modulation

• Neuroprotective activation of hippocampal circuits

Sermorelin itself is not confirmed to cross the blood-brain barrier efficiently, but peripheral GHRH receptor stimulation indirectly influences neuroendocrine pathways.

4. Body Composition & Repair

GH/IGF-1 increases induced by GHRH peptides have been associated in research contexts with:

• Enhanced collagen turnover

• Accelerated wound repair in animal models

• Improved nitrogen retention

These findings apply to mechanistic research use and are not medical claims.

Experimental & Comparative Research

Sermorelin vs. Full-Length GHRH

Studies show GHRH(1-29):

• Maintains full pituitary activity

• Has shorter half-life than endogenous GHRH

• Is less mitogenic than synthetic longer GHRH super-analogs

• Preserves physiologic GH feedback loops

Sermorelin in Pediatric GH Studies

Historically, Sermorelin was used as a diagnostic GH secretagogue to evaluate pituitary GH reserve, demonstrating predictable and reproducible GH stimulation patterns.

Research Use Only – Important Notice

This Sermorelin 5 mg product is supplied strictly for laboratory research purposes.

• Not for human or veterinary use

• Not for diagnostic, therapeutic, or medical application

• For in vitro studies or controlled experimental models only

• Information above summarizes mechanistic and preclinical findings for educational purposes only

References

1. Walker RF et al. Growth hormone–releasing hormone analogues: structure, function, and pharmacology. Endocr Rev. 1991.
https://pubmed.ncbi.nlm.nih.gov/1722164/

2. Thorner MO et al. Stimulation of growth hormone secretion by GRF 1-29 in normal men. J Clin Invest. 1983.
https://pubmed.ncbi.nlm.nih.gov/6605479/

3. Chapman IM et al. Pharmacokinetics and endocrine effects of GHRH1-29 in adults. Clin Endocrinol. 1996.
https://pubmed.ncbi.nlm.nih.gov/8737052/

4. Obál F Jr & Krueger JM. GHRH and sleep physiology. Sleep Medicine Reviews. 2001.
https://pubmed.ncbi.nlm.nih.gov/12531152/

5. Veldhuis JD et al. GHRH control of GH pulse dynamics. Am J Physiol. 1991.
https://pubmed.ncbi.nlm.nih.gov/1872388/

6. Sonntag WE et al. GH/IGF-1 axis and tissue repair in aging animal models. J Gerontol A Biol Sci Med Sci. 2000.
https://pubmed.ncbi.nlm.nih.gov/10819307/